Enlivex (FRA:1BT) Margin of Safety % (DCF Earnings Based): N/A (As of Jun. 28, 2026)


FRA:1BT Enlivex Ltd FRA:1BT
31 GF Score
Price €0.50
! 2 Warning Signs
View Full Analysis

What is Enlivex Margin of Safety % (DCF Earnings Based)?

Margin of Safety % (DCF Earnings Based) = (Intrinsic Value: DCF (Earnings Based) - Current Price) / Intrinsic Value: DCF (Earnings Based).

Note: Discounted Earnings model is only suitable for predictable companies (Business Predictability Rank higher than 1-Star). If the company's Predictability Rank is 1-Star or Not Rated, result may not be accurate due to the low predictability of business and the data will not be stored into our database.

Enlivex's Predictability Rank is 1-Star. Thus, the DCF related results in the screener and portfolio will appear as zero and Margin of Safety % (DCF Earnings Based) is not calculated.

FRA:1BT vs TNXP, UNCY, KRRO: Margin of Safety % (DCF Earnings Based) Comparison

For the Biotechnology subindustry, Enlivex's Margin of Safety % (DCF Earnings Based), along with its competitors' market caps and Margin of Safety % (DCF Earnings Based) data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Enlivex Margin of Safety % (DCF Earnings Based) vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Enlivex's Margin of Safety % (DCF Earnings Based) distribution charts can be found below:

* The bar in red indicates where Enlivex's Margin of Safety % (DCF Earnings Based) falls into.


FRA:1BT
31GF Score
Enlivex Ltd FRA:1BT
Margin of Safety % (DCF Earnings Based) is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Enlivex Business Description

Other Exchanges ENLV:USA
Address 14 Einstein Street, Weizmann Science Park, Ness Ziona, ISR, 7403618
Enlivex Ltd is a clinical stage macrophage reprogramming immunotherapy company currently focused on the late-stage clinical development of Allocetra, a novel therapy designed to treat the joint disease osteoarthritis. Additionally, it has developed a treasury using the RAIN protocol, which currently serves as the primary treasury reserve asset of the company.
31GF Score

Get the complete analysis for FRA:1BT

Margin of Safety % (DCF Earnings Based) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.50
Price